GlassScriptPhysician profile
Virginie Lejeune
NPI 1497524128
$4,266.88
in general payments reported to CMS, 2019-2025
24 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,805 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.39 | 2024-2025 | |
| Janssen Biotech, INC. | $459.64 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $333.56 | 2024-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $289.62 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $273.88 | 2024-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.01 | 2024-2025 | Xifaxan, Trulance |
| Pfizer INC. | $232.08 | 2024-2025 | |
| Ardelyx, INC. | $226.65 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $203.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $201.08 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $140.92 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $125.00 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $118.89 | 2024-2025 | Sutab, Suflave |
| Genzyme Corporation | $110.45 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $104.22 | 2024 | Dificid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $72.02 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $66.30 | 2024-2025 | |
| Celgene Corporation | $46.15 | 2024 | Zeposia |
| Aimmune Therapeutics, INC. | $34.81 | 2025 | Zenpep |
| Evoke Pharma, INC. | $27.41 | 2024-2025 | |
| Vivus LLC | $20.38 | 2025 | Pancreaze |
| Daiichi Sankyo INC. | $19.70 | 2025 | Injectafer |
| Pharmacosmos Therapeutics INC. | $15.22 | 2025 | Monoferric |
| Intercept Pharmaceuticals, INC. | $14.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginie Lejeune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.